LogicBio Therapeutics Provides Business Updates

LEXINGTON, Mass., Dec. 22, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. , a clinical-stage genetic medicine company, today provided updates around its SUNRISE Phase 1/2 clinical trial... | December 22, 2021

Related Keywords

United States ,Saudi Arabia ,Fred Chereau ,Susanr Kahn ,Stephen Jasper ,Adam Daley ,Mariana Nacht ,Tuck School Of Business At Dartmouth ,Drug Administration ,Logicbio Therapeutics Inc ,Nasdaq ,Exchange Commission ,National Tay Sachs Allied Diseases Association ,Gilmartin Group ,Berry Company Public Relations ,European Medicines Agency ,Brown University ,Nomination Of New Generide Development ,Logicbio Therapeutics ,New Generide Development Candidate ,Hereditary Tyrosinemia Type ,From September ,National Tay Sachs ,Allied Diseases Association ,Genzyme Genetics ,Chiron Diagnostics ,Tuck School ,Logicbio Board ,Bio Therapeutics ,Methylmalonic Acidemia ,Private Securities Litigation Reform Act ,Quarterly Report ,Nc Stock Exchange ,News ,Information ,Press Release ,021 ,Enetic ,Medicine ,Oday ,Rovided ,Updates ,Ground ,Its ,Sunrise ,Hase ,Linical Logc Us54142f1021 ,